F2G Raises $70M in Financing

F2G Ltd, a Manchester, UK-based clinical-stage biopharmaceutical company, raised $70 million in financing led by Forbion and Sofinnova Partners, with participation from existing investors. The funds will be used to advance late-stage development and commercialization in the US of olorofim, a novel oral antifungal therapy to treat invasive aspergillosis (IA) and other rare mold infections.

F2G Secures $70 Million to Advance Antifungal Therapy

F2G Ltd is a Manchester, UK-based clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening rare fungal infections with a high unmet medical need. The company has discovered and developed a completely new class of antifungal agents called the orotomides which selectively target a key enzyme in the de novo pyrimidine biosynthesis pathway. Olorofim (formerly, F901318) is F2G’s leading candidate from the orotomide class and is currently in a Phase 2b open-label study (ClinicalTrials.gov Identifier: NCT03583164) in patients who have limited treatment options for difficult-to-treat invasive, rare fungal mold infections such as azole-resistant aspergillosis, scedosporiosis, lomentosporiosis, and other rare mold infections.

A clinical-stage biopharmaceutical company focused on discovering and developing novel therapies to treat life-threatening rare fungal infections with a high unmet medical need.

3 years ago

F2G Secures $70 Million to Advance Antifungal Therapy

ProblemHealthcare

Solution

Covered on